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I have been closely working with Susanne Ragg, M.D., Ph.D. of Indiana University School of Medicine, and Gunther Shadow, M.D., Ph.D. of Regenstrief Institute and Indiana University School of Informatics who performed the direct mentoring and re porting to Dr. McDonald and Dr. Sle dge. Dr. Ragg is also director of Center for Com putational Diagnostics, and it provided me with close co llaborations with researches from different areas of science and m edicine. W e have met weekly at the Ce nter for Computational Diagnostics meetings to discuss the progress. W e have prepared se veral presentations at dis tinct meetings, including my poster presentation at the "Era of Hope" meeting in Baltimore, MD. My mentor in statistics, Krzysztof Podgorski, Ph.D., has moved to accept the chair position o f the Department of Mathematics and Statistics at Lund University, Sweden, while co ntinuing the m entoring and guidanc e for m e through e-m ail, phone, and Skype communications. As the result of this work we are preparing a publication on the alignment of m assspectrometry data. To enhance further m y computational and statistical skills, and to have the direct access, Professor Benzion Boukai, Ph.D., th e chair of the Departm ent of Ma thematical Sciences at Indiana University Purdue University Ind ianapolis agr eed to serve as m y co-m entor in statistics. I will con tinue working closely with my mentors and report directly to them.
Research Project
Objectives/Specific Aims: 1. Develop statistical workflows for th e analysis of plasma/serum samples obtained from large clinical tr ials that leverage the specific requirements of clinical cancer researchers, e.g. a more quantitative approach based on the relative quantification of extracted ion chromatograms from mass spectra of control and experim ental samples and a res triction of the ide ntification process to differentially expressed peptides and proteins, and the incorporation of times series data. 2. Incorporate additional inform ation on the biological aspects of the data such as biological pathways following from genomics studies, prior inform ation on th e studied disease. Test the developed models both on model simulated data and establishe d biological data. Establish sensitivity of the methods as well as their limitations and dependence on the parameters of used technology. 3. Incorporate the developed statistical techniques into the Data Integ rative Specim en Inf ormation Service including visualization tools/packages to aid clinicians in the decision making.
Studies and Results:
The workflow in development can be applied to any disease. We tested it first on a dataset obtained from plasma samples of patients with cardiovascular disease (CVD). Since CVD is one of the most studied diseases, this dataset presented a great opportunity to validate the results by comparing it with known clinical markers from the literature. The clinical trial for breast cancer is still in the stage of samples' collection, and we plan further to refine our workflow and use it on breast cancer samples. We will test it also on the dataset obtained from a study on mice with breast cancer, and on other available datasets.
We are using patients with cardiovascular disease to test the experimental workflow and computational infrastructure for LC-MS/MS-based proteomic experiments as well as for the NMR and MS based metabolomics approach (Specific Aim 1, Research Tasks 1-3). The study cohort involves 3500 patients with coronary artery disease and control patients. Out of this cohort fifty patients, stratified for age and sex, were randomly selected from each of five subgroups; control patients without coronary artery disease, patients with stable angina, patients with unstable angina, patients with non-ST-elevation acute myocardial infarction and patients with ST-elevation acute myocardial infarction. For the LC/MS/MS experiment the high abundance proteins were depleted prior to tryptic digest. Tryptic peptides were analyzed using ThermoFinnigan linear ion-trap mass spectrometry. Spectra were searched using Sequest and X! Tandem, and signal-processed at Monarch Life Science. All data relevant for further interpretation were indexed and integrated in a single relational database. Overall 2581 proteins were identified and quantified. Of these, 198 proteins were identified with high confidence, 749 with intermediate confidence, and 1634 with low confidence. To generate clinically meaningful results, the protein identifications were mapped to high quality publicly available data sources (Specific Aim 2, Research Task 4), including UniProt/SwissProt and NCBI Entrez Gene locus ids and differential quantification was rolled up to the gene level. This improved statistical power and clinical interpretation of the results. The 2581 proteins were combined into, 102 (high confidence identification), 597 (intermediate confidence) and 1317 (low confidence) protein families on the gene level. To achieve a dataset with minimal false identifications, functional annotations from the GeneOntology and the HUPO project were added as well as known plasma concentration from the literature (Research Task 4). Based on this additional information the proteins were assigned a confidence level for the correct identification. Of the 2016 protein families 95 were found to be identified with very high confidence (they were found in the large published HUPO serum protein data set and the serum concentration was in the range that can be measured with LC-MS/MS); 28 were identified with high confidence (12 proteins had borderline reported serum concentrations and 16 proteins were detected in the large HUPO serum protein data set but have not been detected in serum before); 65 protein were identified with intermediate confidence (they had a known extracellular location but were not present in the HUPO data set and no serum concentration was reported in the literature); and 1828 with low confidence. Figure 1 shows the least abundant proteins identifiable by LC-MS/MS in the plasma, after depletion of high abundance proteins (Research Task 6). Peptide abundance was analyzed using the Empirical Bayes approach Limma. Peptide-level quantitative information was combined into protein families using a random-effects model. The list of differentially abundant protein families with a false discovery rate of 0.05 was determined by resampling. The data was annotated with functions from GeneOntology, pathways from Ingenuity Systems, and plasma concentrations from the literature (Specific Aim 2).
Detection and Significant Change by Abundance
To understand the biological relevance of the differentially expressed proteins we used several functional annotation tools. The commercial network prediction tool Ingenuity Pathway Analysis was used to identify relevant pathways and networks. In addition, all proteins were mapped to networks of protein interactions from IntAct. In the case of protein interaction networks, the sub-networks were determined computationally by means of a graph-theoretical algorithm implemented in Bioconductor. Figure 2 shows an example of a global molecular network developed from information contained in the Ingenuity Pathways Knowledge Base, demonstrating the power of looking at protein networks in the overall context. Figure 3 shows the result of the literature and database searches for the functional annotations and biological processes of the differentially expressed proteins(Specific Aims 2 and 3, Research Task 4). Clustering was done independently of the functional annotation by the pattern of each protein across all groups in Bioconductor using Euclidian distance. Results from this study were validated with nephelometry measurements on 11 proteins (Research Task 8). The emerging field of metabolomics promises to add significant new markers to the proteomics approach, and a study of many metabolites together with proteins could become invaluable for a comprehensive pathway and network analysis in cancer. The advantage of analyzing metabolites is that there are much fewer total metabolites in humans (estimated at 3000-5000) compared to proteins. In addition, in response to different physiologic and disease states, metabolites are more prone to perturbations compared to proteins, resulting in changed flux of many metabolites. As part of this project we complemented NMR, which allows for more robust and reproducible measurements, with mass spectrometry-based methods that offer better sensitivity. The NMR experiment resulted in 50 metabolites that were differentially expressed between the 5 groups. The MS data is currently processed and analyzed.
Other Activities
During the last year I mentored several students in the areas related to the project. In order to attract students to this field I have developed and taught the course "Computational Proteomics" in the summer of 2007. The course discussed the modern aspects and tools of high throughput proteomics. To foster the collaboration with researches from industry I have also assisted in the newly organized course BIOS 627 "Statistical Issues in Pharmaceutical Research" taught by researches from Eli Lilly & Company.
Key Research Accomplishments:
-Developed the preliminary version of computational/statistical workflow for analysis of data from clinical studies based on high throughput technologies such as mass-spectrometry and protein microarrays of plasma/blood -Incorporated prior biological knowledge from biological pathways and public databases -Tested the developed workflow on patients with cardio vascular diseases -Compared found proteins with known results from the literature and validated it versus laboratory essay on 11 proteins
Conclusion:
In our study we demonstrate how global proteomic study of plasma can be used to classify the risk of cardiac events. Moreover, we aim the goal of presenting a panel of proteins that can be used for this purpose in the clinical study. Further, to improve the sensitivity we study the biological pathways and plan to include other variables in the study, such as the gene expression data from microarrays and targeted mass spectrometry of proteins of interest and cytokines, as well as clinical data. The developed workflow will be put in use for breast cancer samples when available.
We will complete metabolomic analyses within the next 12 months. We will perform protein microarray analysis on the serum of the 250 patients with cardiovascular disease. We will develop workflows for the analysis of protein microarrays and merge it with mass-spectrometry proteomic analysis. At this point we have available mass-spectrometry data of mice with breast cancer. We will apply our developed proteomic workflow on this dataset. Over the next twelve months we will also continue to improve the Data Integrative Specimen Information Service, and include workflows for the analysis of protein microarrays. Cluster analysis is one of the commonly used exploratory techniques based on measure of dissimilarity between cases. They are typically grouped into hierarchical and partitioning methods, and usually it is not a straightforward task which technique should be used in a given problem. It is natural to see clustering of results in medical literature, where most researchers would implement one or another type of so-called heatmap and/or dendrogram representation of clustering results. The obvious advantage of these approaches is the visual ability to recognize patterns. However, clustering methods are not always the best visualization technique; moreover, due to the vast variety of clustering methods, in many cases giving different answers, there's a danger of over-interpretation of data, and one should use it only as a hypothesis generating procedure rather than ultimate solution to multivariate problems. In this presentation we discuss the small piece of our work on how one can use clustering in interpretation of proteomics data. We follow the approach commonly used in the microarray analysis. For this study we used the data obtained by the collaborative group of researchers of the Center for Computational Diagnostics at the Indiana University. Blood was obtained from patients seen at the Heart Center, Munich, Germany over a period of one year. We randomly selected a total of 250 patients for this experiment out of the 3500 who had plasma collected. Fifty patients, stratified for age and sex, were randomly selected from five disease subgroups. Samples were randomized into 2 batches with 5 groups per batch. Randomization was stratified by disease group and age. High Abundance Proteins were depleted from the plasma samples using the commercially available albuminremoval kit (Montage, Millipore). All plasma samples were denatured by 8M urea, digested by trypsin and processed for LC/MS/MS analysis using Thermo-Finnigan linear ion-trap mass spectrometer (LTQ) by the Indiana Center for Applied Protein Sciences. We have 3 basic layers of data: the raw data (basically the spectra of individual ions from MS), the identified and somewhat quantified peptides, and finally the protein identification and quantification. The raw data, while the vast and extremely complex, is the only "true" dataset; however, in clinical settings one needs to be able to interpret the biological meaning of data such as protein expressions. Moreover, the clustering techniques become obsolete due to the complexity and noise present in the data. The peptide level, while simpler, still doesn't provide either the desired interpretation or ability to use clustering. As a simple example, let us compare two heatmaps below: one done on the peptide level for all patients, and another on selected group of proteins and mean differences in patient groups. The first picture bears no sense at all, while the second can be used for further investigation, for example, to study the possible pathways among the clusters of proteins.
Another approach is to look how different gene (or protein) annotations are distributed among our set of proteins and whether they express similar behavior. For example, for the data in our experiment it is known that acute phase reactants play important role. So we can look if they group together by marking them blue in the dendrogram below.
Obviously some of them cluster together and some do not. So, one can ask whether this information provides any leads toward better understanding of the biology of the disease. In fact, in the case above, one of proteins not marked originally in blue, i.e., not classified as being an acute phase, after the investigation was found to be in the same pathway. These are only two examples out of many hundreds that typically a researcher would go through while studying similar datasets. Clustering provides simple way to look for hypothesis. In no way it should be presented as a final answer, and one should be very suspicious of the results claimed on the base of clustering techniques only. In our project we use the tool commonly used in microarrays analysis for the new field of proteomics. While one can not apply it directly, after some modifications it shows great potential. 
Germany
Clinical applications of cancer proteomics include disease marker discovery for diagnosis, prognosis, and drug response as well as characterization of signaling and protein pathways. Due to the large dynamic range over which proteins must be detected in plasma (10 10 ), several techniques for identifying differentially expressed proteins have to be combined, such as liquid chromatography followed by mass spectrometry and multiplex antibody arrays. High-throughput technology such as mass spectrometry requires large sample sizes, and the sheer volume of data collected during LC-MS/ MS analysis of plasma samples (1.4 GB) requires that the workflow for data analysis is automated.
One of the major challenges of global proteomics is the lack of rigorous mathematical and statistical tools for analysis of data. While some techniques were developed in genomic studies for microarrays, they cannot be applied directly. For example, in microarrays, one immediately has the intensities for an object of interest, for example, genes, while in the MS/MS proteomics, the quantitative information is obtained for peptides and has to be combined into proteins.
The clinical global proteomics experiment is typically comprised of the following steps:
Design of Experiment:
A mass spectrometry experiment should be carefully designed to include numerous factors in randomization and stratification scheme.
Collection of Samples

Preparation of Samples:
To increase the sensitivity and to be able to detect the lower abundant proteins, highabundance proteins are depleted prior to tryptic digestion.
LC-MS/MS:
The analysis of tryptic peptides is performed by Thermo-Finnigan linear ion-trap mass spectrometer at Monarch Life Sciences.
Identification and Quantification of Peptides:
The obtained spectra are searched over public databases, and peptides are quantified.
Quantification of Proteins:
Since the database search does not provide the definite answer for similar proteins, such as in the case of polymorphic protein variances, we combine peptide-level quantitative information into protein families on the gene level.
